Bispecific antibody treatment of refractory HER2-positive breast cancer has positive clinical results

A few days ago, Zymeworks announced that its HER2 bispecific antibody zanidatamab, combined with chemotherapy, has shown encouraging results in a phase 1 clinical trial for the treatment of refractory HER2-positive breast cancer patients who have received multiple pre-treatments.

Although patients with HER2-positive breast cancer have a variety of treatment options, many advanced patients still have disease progression

▲Zanidatamab has a unique mechanism of action (picture source: Zymeworks official website)

The full results of this trial will be announced at the San Antonio Breast Cancer Symposium (SABCS) in early December

The results of the trial showed that among the 16 patients whose response could be assessed, the combination therapy achieved an objective remission rate of 37.

In terms of safety, treatment-related adverse events are consistent with the previously reported safety characteristics of zanidatamab and chemotherapy, and most of the adverse events were grade 1 or 2

In addition to the treatment of breast cancer, zanidatamab has obtained breakthrough therapy designation granted by the FDA for the treatment of biliary tract cancer with amplification of the HER2 gene, and fast-track qualification for the first-line treatment of gastroesophageal adenocarcinoma in combination with chemotherapy

Reference materials:

[1] Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS).